These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 39116938

  • 1. Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors + Mycophenolate Mofetil versus Sirolimus + Mycophenolate Mofetil.
    Esquirol A, Pascual MJ, Montoro J, Piñana JL, Ferrà C, Herruzo B, Garcia-Cadenas I, Balaguer A, Perez A, Huguet M, Redondo S, Villalba M, Hernandez-Boluda JC, Chorao P, Hernani R, Sanz J, Solano C, Sierra J, Martino R.
    Transplant Cell Ther; 2024 Oct; 30(10):1025.e1-1025.e14. PubMed ID: 39116938
    [Abstract] [Full Text] [Related]

  • 2. Uniform Graft-versus-Host Disease Prophylaxis using Post-Transplantation Cyclophosphamide, Methotrexate, and Cyclosporine following Peripheral Blood Hematopoietic Stem Cell Transplantation from Matched and Haploidentical Donors for Transfusion-Dependent Thalassemia: A Retrospective Report from the Bone Marrow Failure Working Group of Hunan Province, China.
    Gong S, Tian X, Yang R, Yang L, Wang Z, Yang K, Chen K, He X, Deng W, Yang X, Lei M, Fu B.
    Transplant Cell Ther; 2024 Dec; 30(12):1213.e1-1213.e12. PubMed ID: 39236789
    [Abstract] [Full Text] [Related]

  • 3. Biologically Randomized Comparison of Haploidentical Versus Human Leukocyte Antigen-Matched Related Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.
    Grunwald MR, Sha W, He J, Sanikommu S, Gerber JM, Ai J, Knight TG, Fasan O, Boseman V, Kaizen W, Chojecki A, Ragon BK, Symanowski J, Avalos B, Copelan E, Ghosh N.
    Transplant Cell Ther; 2024 Dec; 30(12):1211.e1-1211.e11. PubMed ID: 39332808
    [Abstract] [Full Text] [Related]

  • 4. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.
    Kiene S, Albrecht M, Theurich S, Scheid C, Skoetz N, Holtick U.
    Cochrane Database Syst Rev; 2024 Nov 07; 11(11):CD010189. PubMed ID: 39508306
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Methotrexate Versus Mycophenolate Mofetil Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis on Behalf of the Chronic Malignancies Working Party of the EBMT.
    Luft T, Gras L, Koster L, Kröger N, Schröder T, Platzbecker U, Sockel K, de Latour RP, Stelljes M, Sengeloev H, Eder M, Blau IW, Dreger P, Yakoub-Agha I, Maertens J, Salmenniemi U, Bethge W, Mielke S, Kobbe G, Pouli A, de Wreede LC, Raj K, Drozd-Sokolowska J, McLornan DP, Robin M.
    Am J Hematol; 2025 Jan 07; 100(1):38-51. PubMed ID: 39605194
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Allogeneic Hematopoietic Cell Transplant For Bone Marrow Failure or Myelodysplastic Syndrome in Dyskeratosis Congenita/Telomere Biology Disorders: Single-Center, Single-Arm, Open-Label Trial of Reduced-Intensity Conditioning Without Radiation.
    Dimitrov M, Merkle S, Cao Q, Tryon RK, Vercellotti GM, Holtan SG, Kao RL, Srikanthan M, Terezakis SA, Tolar J, Ebens CL.
    Transplant Cell Ther; 2024 Oct 07; 30(10):1005.e1-1005.e17. PubMed ID: 39002862
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy of a Modified Post-Transplant Cyclophosphamide Regimen for Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Severe Aplastic Anemia: A Prospective Study.
    Chen X, Chen C, Zhou M, Zhang Y, Wang C, Li Y, Zhou R, Xu S, Zhou W, Deng T, Pan S, Wu L, Zhang Y, Mo W, Wang S.
    Transplant Cell Ther; 2024 Nov 07; 30(11):1099.e1-1099.e10. PubMed ID: 39187160
    [Abstract] [Full Text] [Related]

  • 13. Venous Thromboembolism Incidence and Risk Factors in Patients Undergoing Hematopoietic Stem Cell Transplantation.
    Benfield M, He J, Arnall J, Kaizen W, Jandrisevits E, Eboli-Lopes K, Dodd B, Grunwald MR, Avalos B, Copelan E, Patel JN.
    Transplant Cell Ther; 2024 Nov 05. PubMed ID: 39505211
    [Abstract] [Full Text] [Related]

  • 14. Long-term follow-up of the randomized, prospective Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trial.
    Bollano E, Andreassen AK, Eiskjaer H, Gustafsson F, Rådegran G, Gude E, Gullestad L, Broch K, Halden TAS, Karason K, Bartfay SE, Bergh N, SCHEDULE (Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance) investigators.
    J Heart Lung Transplant; 2024 Dec 05; 43(12):1948-1959. PubMed ID: 39038562
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of Nonrelapse Mortality After Haploidentical Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide Versus Single Umbilical Cord Blood Transplantation in Hematologic Disease.
    Harada K, Kanda J, Hirayama M, Wada F, Uchida N, Tanaka M, Nakamae H, Tokunaga M, Ishiwata K, Onizuka M, Hasegawa Y, Fukuda T, Eto T, Kurita N, Kawakita T, Jinguji A, Ishimaru F, Atsuta Y, Nakasone H.
    Transplant Cell Ther; 2024 Nov 26. PubMed ID: 39603416
    [Abstract] [Full Text] [Related]

  • 17. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006-2010.
    Naidu L, Chiu C, Habig A, Lowbridge C, Jayasinghe S, Wang H, McIntyre P, Menzies R.
    Commun Dis Intell Q Rep; 2013 Dec 31; 37 Suppl():S1-95. PubMed ID: 24410428
    [Abstract] [Full Text] [Related]

  • 18. [Short-term substitution of calcineurin inhibitors (CNI) with recombinant humanized anti-CD25 monoclonal antibody (Basiliximab) as aGVHD prophylaxis in CNI intolerant patients after allogeneic hematopoietic stem cell transplantation].
    Shao S, Liu HX, Jiang Y, Li S, Wei DL, Zhu J, Wang C, Zhao CX.
    Zhonghua Xue Ye Xue Za Zhi; 2024 Feb 14; 45(2):115-120. PubMed ID: 38604786
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Early Mixed Donor Chimerism is a Strong Negative Prognostic Indicator in Allogeneic Stem Cell Transplant for AML and MDS.
    Radford M, Garcia-Horton A, Badami R, Jin E, Usmani N, Grafodatskaya D, McCready E, Khalaf D, Walker I, Leber B, Lepic K, Pond G, Berg T.
    Transplant Cell Ther; 2024 Nov 14. PubMed ID: 39547311
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.